TandemAI
TandemAI is an integrated drug discovery contract research organization (CRO) that combines proprietary AI and physics-based computational methods with in-house high-performance computing and extensive wet-lab operations to accelerate pharmaceutical research. Its cloud-enabled, data-centric, browser-based platform, TandemViz, spans hit finding, hit-to-lead and lead optimization, digital assays and workflows, medicinal chemistry and synthesis, biological assays, and a peptide platform. TandemAI is offered as an FTE-based service model that bundles wet-lab services with complimentary access to its AI and computational tools, or as a stand-alone SaaS software license. The company merged with Perpetual Medicines and is backed by Qiming Venture Partners.
TandemAI is profiled on the APIs.io network. Tagged areas include Company, Drug Discovery, Artificial Intelligence, Computational Chemistry, and Biotechnology.
TandemAI’s developer surface includes engineering blog, support, and 5 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Get Started 1
Portal, sign-up, and the first successful call
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 2
The organization behind the API